# Neuropace, Inc. (NPCE) Stock Analysis: Analyst Ratings Suggest 62% Upside Potential

- Link: https://www.directorstalkinterviews.com/neuropace-inc-npce-stock-analysis-analyst-ratings-suggest-62-upside-potential/4121216919
- Published: 2025-09-19T10:27:09+01:00
- Author: Madison Wilson

Neuropace, Inc. (NPCE), a pioneer in the healthcare sector specializing in medical
devices, has captured investor attention with its innovative solutions for treating
drug-resistant focal epilepsy. With a market capitalization of $341.4 million, Neuropace
remains a dynamic player in the medical device industry, particularly known for 
its RNS System—a brain-responsive neuromodulation system that offers personalized,
real-time treatment at the seizure source.

Currently trading at $10.32, Neuropace’s stock price has experienced a modest increase
of $0.43, or 0.04%. This movement comes amidst a 52-week price range of $5.90 to
$18.13, highlighting the stock’s volatility and potential for growth. Notably, analysts
have set a target price range of $13.00 to $20.00, with an average target price 
of $16.75, indicating a potential upside of approximately 62.31%.

Despite the promising outlook, investors should be aware of the company’s current
financial metrics. Neuropace does not yet demonstrate profitability, as evidenced
by the absence of a trailing P/E ratio and a negative forward P/E of -15.25. The
company’s revenue growth is a robust 22.10%, but challenges remain in terms of net
income and EPS, which stands at -0.82. Return on Equity is notably low at -176.94%,
and free cash flow is in the red at -$7.6 million, suggesting that the company is
still in the early stages of scaling its operations.

In terms of technical indicators, Neuropace’s stock is trading below its 200-day
moving average of $11.47 but above its 50-day moving average of $9.20, which may
present a buying opportunity for investors looking to capitalize on short-term price
movements. The Relative Strength Index (RSI) is at 20.37, indicating that the stock
may be oversold, potentially signaling a forthcoming price correction. The MACD 
indicator, with a value of 0.24 against a signal line of 0.15, suggests a bullish
trend in the near term.

A key point of confidence for potential investors is the unanimous analyst sentiment,
with eight buy ratings and zero hold or sell ratings. This level of consensus among
analysts underscores the market’s optimism about Neuropace’s growth trajectory and
the potential impact of its technology on patient care.

While Neuropace does not offer dividends, reflecting its current focus on reinvestment
and growth, the company’s strategic initiatives and innovative product offerings
position it well for future expansion. As Neuropace continues to refine its RNS 
System and expand its market reach, investors will be closely monitoring its progress
towards profitability and its ability to sustain revenue growth.

For investors with a tolerance for risk and a keen interest in the healthcare sector,
Neuropace presents an intriguing opportunity. The combination of innovative technology,
significant analyst support, and a substantial potential upside makes NPCE a stock
worth watching in the coming months. As always, investors are encouraged to conduct
thorough due diligence and consider their individual risk tolerance before making
investment decisions.

Share on: